Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

NASDAQLPCN
FormDescriptionDateFormat
CT ORDERConfidential treatment orderJul 26, 2016View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 16, 2016View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2016View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 10, 2016View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GJan 12, 2016View HTMLDownload DOCDownload PDF